Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Geriatrics Oncology
•
Supportive Care
How do you mitigate cognitive slowing in elderly patients with mCSPC receiving LHRH agonist therapy?
Do you switch medications or offer adjunct therapies? What works well in your practice?
Related Questions
For patients who progress to mCRPC on ADT+ARSI started in mCSPC setting, do you continue the ARSI if patients have had a mixed response?
Would you consider a cycle of EP in a patient with good risk stage IIIB seminoma on BEP but with bleomycin omitted for cycle 3?
Is there a clinical benefit for a repeat TURBT to ensure complete resection of the bladder tumor prior to neoadjuvant chemotherapy and radical cystectomy?
Would you offer neoadjuvant chemotherapy to high grade T1 urothelial carcinoma in a bladder diverticulum?
What is your preferred approach to low volume unresectable/metastatic favorable risk RCC?
Would you use adjuvant pembrolizumab for bilateral ccRCC with R1 resection?
How would you sequence therapy for patient with metastatic RCC who was not able to tolerate TKI but now have progress on single agent IO?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
What is the optimal approach for high risk prostate cancer patients who have been found to have positive nodes after surgery?
How do you consider the role of probiotics for mucositis mitigation in patients receiving head and neck radiotherapy?